Takeda Pharmaceutical (NYSE:TAK) Company Limited is a global biopharmaceutical company headquartered in Japan. The company researches, develops, manufactures and markets prescription medicines and vaccines for patients and healthcare professionals around the world.
Takeda focuses on several therapeutic areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Ninlaro for multiple myeloma and Iclusig for certain blood cancers, along with other specialty medicines and vaccines.
Founded in Osaka in 1781, Takeda has grown from a traditional pharmaceutical distributor into an international biopharmaceutical company serving markets across Japan, North America, Europe and other regions. The company expanded significantly through its acquisition of Shire plc, completed in 2019, which strengthened its presence in rare diseases and specialty medicines.
Takeda's American depositary shares trade on the New York Stock Exchange under the symbol TAK, while its ordinary shares are listed in Japan. Christophe Weber has served as the company's president and chief executive officer since 2014.
